APIM Therapeutics AS

APIM Therapeutics AS is a biotechnology subsidiary funded by venture capital from the Norwegian University of Science and Technology (NTNU, Trondheim). The company is currently developing patented peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein that regulates cellular responses to DNA damage and stress.